Soleno Therapeutics Reports Q4 and Full-Year 2022 Financial Results, Provides Clinical Update

SOLENO THERAPEUTICS INC

Enrollment nearing completion in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.
Securities purchase agreement with Nantahala Capital, Abingworth, and Vivo Capital for up to $60 million in gross proceeds.
Cash and cash equivalents of $14.6 million as of December 31, 2022.
Net loss of $5.5 million for Q4 2022, compared to $2.8 million in Q4 2021.
R&D expenses were $3.8 million for Q4 2022, compared to $3.7 million in Q4 2021.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SOLENO THERAPEUTICS INC reported the year ended December 31, 2022 results: net income approximately $24.1 million, EPS $2.87 per basic and diluted share.

Period: the year ended December 31, 2022
Net income: approximately $24.1 million
EPS: $2.87 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2022, was approximately $24.1 million, or $2.87 per basic and diluted share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SOLENO THERAPEUTICS INC reported the fourth quarter ended December 31, 2022 results: net income approximately $5.5 million, EPS $0.58 per basic and diluted share.

Period: the fourth quarter ended December 31, 2022
Net income: approximately $5.5 million
EPS: $0.58 per basic and diluted share
Result: reported results

Exact text from the filing

Net loss was approximately $5.5 million, or $0.58 per basic and diluted share, for the quarter ended December 31, 2022

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

SOLENO THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-23-075734

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.